1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Oncolys BioPharma, Inc.

Oncolys BioPharma, Inc.

TTSE:4588
5,930.00
JPY
+330.00
(+5.89%)
86.62BMarket Cap
Nov 06Next Earn
Oncolys BioPharma, Inc.
TSE:4588
(Tokyo Stock Exchange)

Recent

price

5,930.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
64.95
0.18
3.14
13.21
19.37
22.32
14.28
93.68
21.83
37.98
56.34
3.54
1.44
1.11
- -
Revenue per Share
-16.83
-94.33
-80.55
-93.35
-101.18
-106.23
-104.55
-65.55
-145.58
-95.5
-66.31
-108.92
-77.17
-80
- -
Basic EPS, GAAP
-27.3
-88.94
-91.29
-82.75
-100.42
-106.97
-100.77
-17.43
-102
-103.06
-99.18
-75.44
-92.69
-75.56
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
52.05
561.17
476.03
381.27
283.43
264.47
217.38
241.27
136.96
207.31
124.65
75.1
110.71
136.64
111.19
Book Value per Share
51.87
561.03
475.94
380.82
283.43
264.47
217.38
241.21
136.91
207.31
124.65
75.1
110.71
136.64
111.19
Tangible Book Value per Share
6
7
9
9
9
10
12
14
14
17
17
18
22
26
28
Basic Weighted Avg Shares
397
1
29
121
178
229
169
1,304
314
642
976
63
31
29
- -
Sales/Revenue/Turnover
-35.53
-56,395.08
-2,874.41
-784.46
-483.03
-470.63
-740.18
-39.23
-533.03
-226.39
-123.39
-3,061.62
-5,357.52
-7,090.55
- -
Operating Margin (%)
17
17
13
17
15
1
2
3
5
6
1
2
1
- -
- -
Depreciation Expense
-103
-636
-739
-857
-931
-1,091
-1,234
-912
-2,095
-1,615
-1,149
-1,939
-1,685
-2,058
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-25.92
-53,860.42
-2,566.24
-706.73
-522.34
-476
-732.04
-69.97
-666.85
-251.43
-117.7
-3,075.14
-5,368.27
-7,209.59
- -
Profit Margin (%)
640
5,398
4,622
3,497
2,542
2,833
2,406
3,303
2,130
3,768
2,287
1,577
2,846
4,024
3,319
Working Capital
228
359
366
325
315
352
312
397
373
262
162
180
187
76
103
LT Debt
472
5,094
4,371
3,501
2,617
2,932
2,901
3,454
2,003
3,594
2,159
1,474
2,752
4,000
3,257
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-22.84
-15.62
-21.78
-30.44
-39.31
-42.31
-28.71
-76.78
-57.72
-39.94
-106.71
-79.73
-60.96
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
156
- -
697
LT Borrowings
194
- -
97
LT Finance Leases
15
- -
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
29
29
Market Capitalization
11,436
63,168
86,625

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
1,770
- -
4,460
Cash, Cash Equivalents & STI
1,118
- -
3,187
Accounts Receivable, Net
32
- -
582
Inventories
4
- -
4
Total Current Liabilities
252
- -
1,141
Payables & Accruals
- -
- -
- -
ST Debt
156
- -
697
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.26%
27.96%
45.34%
Free Cash Flow
51.66%
8.45%
-3.94%
Net Income, GAAP
16.85%
5.2%
22.16%
Sales/Revenue/Turnover
65.04%
0.73%
-9.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
31
- -
- -
31
2025
- -
- -
- -
- -
29
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-18.24
-18.73
- -
- -
-77.17
2025
- -
- -
- -
- -
-80
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Oncolys BioPharma Inc. Oncolys BioPharma Inc. is a biopharmaceutical company focused on the research, development, manufacturing, sale, import, and export of oncolytic viruses, pharmaceuticals, and tumor diagnostic agents targeting cancer and infectious diseases. The company operates through two primary segments, including the pharmaceutical business developing novel therapies such as Telomelysin (OBP-301), a telomerase-specific oncolytic adenovirus in phase II trials for esophageal cancer/gastroesophageal junction tumors by Chugai Pharmaceutical, phase I/II for head and neck cancer combinations with pembrolizumab and radiation, and phase I for hepatocellular carcinoma (HCC) both as monotherapy and combined with atezolizumab plus bevacizumab; OBP-702 for solid tumors in preclinical stages; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor completed in phase IIb for HIV; OBP-801, a histone deacetylase inhibitor in phase I for solid tumors; and diagnostics business offering TelomeScan (OBP-401 and OBP-1101) for detecting circulating tumor cells along with related inspection services. Founded on March 18, 2004, and headquartered in Minato-ku, Tokyo, Japan, with facilities in Kobe, Japan, and subsidiaries Oncolys USA Inc. in New Jersey and OPA Therapeutics Inc., it conducts operations in Japan, the United States, and other Asian regions through licensing agreements with entities including Okayama University, National Cancer Center Hospital East, Cornell University, Medigen Biotechnology Corp., Astellas Pharma Inc., and Chugai Pharmaceutical. Recent developments encompass ongoing clinical progress by partners such as Chugai Pharmaceutical advancing Telomelysin combinations into phase II for esophageal cancer and phase I for HCC and head and neck applications; private placements including 40,000 Series 20 stock acquisition rights issued to EVO FUND in June 2024 for gross proceeds of 2.2 million yen closing July 2024 and additional 43,300 rights at 920 yen each announced in July 2025; and investigator-initiated phase I/b and phase II trials for Telomelysin plus pembrolizumab in advanced solid tumors and esophageal cancers.